Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchBebtelovimabBebtelovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Bebtelovimab for COVID-19: real-time meta analysis of 6 studies

@CovidAnalysis, February 2024, Version 16V16
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Lilly (RCT) -201% 3.01 [0.12-73.2] death 1/127 0/128 Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Lilly (RCT) -51% 1.51 [0.26-8.90] hosp. 3/127 2/128 Lilly (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Lilly (RCT) 38% 0.62 [0.35-1.10] viral+ 16/127 26/128 Lilly (RCT) 33% 0.67 [0.38-1.17] viral+ 17/125 26/128 BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 BLAZE-4 Dougan (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 BLAZE-4 Dougan (RCT) 4% 0.96 [0.95-0.97] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 30% 0.70 [0.63-0.78] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 15% 0.85 [0.81-0.88] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 39% 0.61 [0.34-1.11] viral+ 15/125 25/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Dryden-Peterson 43% 0.57 [0.28-1.19] death/hosp. 10/377 17/377 Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Molina 59% 0.41 [0.17-1.03] ICU 6/3,739 21/5,423 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Molina (PSM) 46% 0.54 [0.38-0.74] hosp. 48/3,739 116/5,423 Molina (PSM) -33% 1.33 [1.12-1.57] progression 260/3,739 275/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Sridhara (PSM) 25% 0.75 [0.43-1.31] death/hosp. 24/1,091 28/1,091 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Bebtelovimab COVID-19 outcomes c19early.org February 2024 Favors bebtelovimab Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit